Pembrolizumab‐Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review
ABSTRACT Background Pembrolizumab, an anti‐PD‐1 immune checkpoint inhibitor, has transformed the treatment of multiple solid tumors. However, it can rarely cause immune‐related myositis, which may involve limb, bulbar, and respiratory muscles, posing a risk of severe morbidity and mortality. Early r...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2026-06-01
|
| Seri Bilgileri: | Cancer Reports |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/cnr2.70534 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|